<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931475</url>
  </required_header>
  <id_info>
    <org_study_id>13494</org_study_id>
    <secondary_id>F1J-MC-HMGS</secondary_id>
    <nct_id>NCT01931475</nct_id>
  </id_info>
  <brief_title>A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China</brief_title>
  <official_title>Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of duloxetine once daily
      compared with placebo on the reduction of pain due to osteoarthritis (OA) in knee or hip in
      participants in China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Brief Pain Inventory (BPI) 24-hour Average Pain Score</measure>
    <time_frame>Baseline, Week 13</time_frame>
    <description>BPI is a self-reported scale that measures the severity of pain based on the average pain during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impressions of Improvement (PGI-I) Score</measure>
    <time_frame>13 Weeks</time_frame>
    <description>PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total and Subscale Scores</measure>
    <time_frame>Baseline, Week 13</time_frame>
    <description>WOMAC consists of 24 items divided into 3 subscales:Pain(5 items):during walking,using stairs,in bed,sitting or lying,and standing Stiffness;(2 items):after first waking and later in the day Physical Function;(17 items):stair use,rising from sitting, standing, bending,walking,getting in/out of a car,shopping,putting on/taking off socks,rising from bed,lying in bed,getting in/out of bath,sitting,getting on/off toilet,heavy household duties,light household duties.Each question is answered using a 5-point Likert scale(0 to 4).Pain subscale has a range of scores of 0(none) to 20(extreme).Stiffness subscale has a range of scores of 0(none) to 8(extreme).Physical function subscale has a range of scores of 0(none) to 68(extreme).Total score ranges from 0(none) to 96(extreme).Least squares(LS) mean was calculated using analysis of covariance(ANCOVA) and adjusted for treatment, pooled investigator,and baseline score.Last observation carried forward (LOCF) method was be used for these analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score</measure>
    <time_frame>Baseline,13 Weeks</time_frame>
    <description>CGI-S measures severity of illness at the time of assessment compared with start of treatment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory (BPI) Severity</measure>
    <time_frame>Baseline, Week 13</time_frame>
    <description>BPI Severity of Worst Pain is self-reported scale that measures the severity of pain based on the worst pain experienced during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). BPI Severity of Least Pain is a self-reported scale that measures the severity of pain based on the least pain experienced during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). BPI Severity of Right Now Pain is a self-reported scale that measures the severity of pain based on the pain right now. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory (BPI) Interference</measure>
    <time_frame>Baseline, Week 13</time_frame>
    <description>BPI Interference Average Score is a self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people,sleep, and enjoyment of life.The average Interference scores ranged from 0 to 10. General activity, mood,walking ability, normal work,relations with other people, sleep and enjoyment of life is each is a self-reported scale that measures the interference of pain in the past 24 hours on general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life.The Interference scores ranged from 0 (does not interfere) to 10 (completely interferes).Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hospital Anxiety and Depression Scale-Depression (HADS-D) or HADS-Anxiety (HADS-A) Subscale Scores</measure>
    <time_frame>Baseline, Week 13</time_frame>
    <description>HADS is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale [0 (low level of anxiety or depression) to 3 (high level of anxiety or depression)], giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale were considered to be a 'significant' case of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' Mean was calculated using analysis of covariance (ANCOVA) and adjusted for treatment, pooled investigator, and baseline score. The last observation carried forward (LOCF) method will be used for these analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Pain Inventory (BPI) Average Pain Intensity Scores, Hospital Anxiety and Depression Scale (HADS) Depression Subscale (HADS-D) and HADS Anxiety Subscale (HADS-A)</measure>
    <time_frame>Baseline, Week 13</time_frame>
    <description>Evaluation on whether the change in BPI average pain intensity scores is a direct analgesic effect of duloxetine and is independent of treatment effect on mood, as measured by Hospital Anxiety and Depression Scale (HADS) depression subscale (HADS-D), or anxiety as measured by HADS anxiety subscale (HADS-A). Path analysis for the direct analgesic effect was used to test the null hypothesis that the change in BPI average pain severity depends on the improvement of HADS-D or HADS-A, versus the alternative that the improvement in BPI average pain severity is due to a direct analgesic effect of the treatment and not dependent upon the improvement in depression and anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reduction of ≥30% and ≥50% in BPI Average Pain Score</measure>
    <time_frame>Week 13</time_frame>
    <description>Pain severity was measured using an 11 point BPI scale from 0 (no pain) to 10 (worst pain) to determine average pain in the past 24 hours (average pain). A 30% (or 50%) improvement was defined as a ≥30% (or ≥50%) reduction in BPI pain severity from baseline to endpoint. Percentage of participants = (number of participants with ≥30% or ≥50% pain reduction / total number of participants in treatment group) * 100.The last observation carried forward (LOCF) method will be used for these analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response to Treatment on Patient Global Impression-Improvement (PGI-I) at Endpoint</measure>
    <time_frame>Week 13</time_frame>
    <description>PGI-I measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). Response to treatment is defined by endpoint PGI rating of either &quot;much better&quot; or &quot;very much better&quot;.The last observation carried forward (LOCF) method will be used for these analyses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">407</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>LY248686</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet clinical and radiographic criteria for the diagnosis of OA of the knee or hip
             with pain for ≥14 days of each month for 3 months prior to study entry

          -  Have a rating ≥4 on the Brief Pain Inventory (BPI) 24-hour average pain item (Question
             3 of the BPI modified short form) at both Screening and Randomization

        Exclusion Criteria:

          -  Have previously completed/withdrawn from this study or any other study investigating
             duloxetine (Note: Participants who have been previously screened for a duloxetine
             study other than this study and never received investigational product will be
             eligible for this study if they meet all current entry criteria)

          -  Have had previous exposure to duloxetine

          -  Have any previous diagnosis of psychosis, bipolar disorder, or schizoaffective
             disorder

          -  Current (within 1 year of Screening) Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition Axis I diagnosis of major depressive disorder, anxiety
             disorders (excluding phobias), alcohol or eating disorders, as determined by the
             Mini-International Neuropsychiatric Interview or a previous diagnosis

          -  Have a history of substance abuse or dependence within the past year, excluding
             nicotine and caffeine

          -  Are taking any excluded medications that cannot be discontinued at Screening

          -  Have had treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of
             randomization or the potential need to use an MAOI during the study or within 5 days
             of discontinuation of investigational product

          -  Have a positive urine drug screen for any substance of abuse or excluded medication

          -  Have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or
             other medical or psychiatric condition that, in the opinion of the investigator, would
             compromise participation or be likely to lead to hospitalization during the course of
             the study

          -  Have a history of recurrent seizures other than febrile seizures

          -  Are judged clinically by the investigator to be at suicidal risk according to the
             Columbia - Suicide Severity Rating Scale (C-SSRS): a &quot;Yes&quot; answer to either Question 4
             (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question
             5 (Active Suicidal Ideation with Specific Plan and Intent) on the&quot;Suicidal Ideation&quot;
             portion of the C-SSRS or a &quot;Yes&quot; answer to any of the suicide related behaviors
             (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on
             the &quot;Suicidal Behavior&quot; portion of the C-SSRS, with the ideation/behavior having
             occurred within the previous month

          -  Have uncontrolled narrow-angle glaucoma

          -  Have acute liver injury (such as hepatitis) or severe cirrhosis

          -  Have known hypersensitivity to duloxetine or any of the inactive ingredients or have
             frequent/severe allergic reactions to multiple medications

          -  Have frequent falls that could result in hospitalization or could compromise response
             to treatment

          -  Have a diagnosis of inflammatory arthritis [that is, rheumatoid arthritis (RA)] or an
             autoimmune disorder (excluding inactive Hashimoto's thyroiditis)

          -  Have received intra-articular hyaluronate/steroids, joint lavage, or other invasive
             therapies to the index joint in the previous 3 months

          -  Have had arthroscopy of the index joint within the previous year or joint replacement
             of the index joint at any time

          -  Have surgery of the index joint scheduled to occur during the trial or are anticipated
             by the investigator to require surgery for the treatment of the OA of the index hip or
             knee along the duration of the study

          -  Have had a prior synovial fluid analysis showing a white blood cell (WBC) count ≥2000
             cubic millimeter (mm3) that is indicative of a diagnosis other than OA

          -  Are non-ambulatory or require the use of crutches or a walker

          -  Have a body mass index &gt;40

          -  Are anticipated by the investigator to require use of analgesic agents including, but
             not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs),
             acetaminophen/paracetamol, and opioids, or other excluded medication for the duration
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5PM Eastern Time (UTC/GMT-5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eil Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bengbu</city>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changchun</city>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pingxiang</city>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zhuzhou</city>
        <zip>412007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <results_first_submitted>February 29, 2016</results_first_submitted>
  <results_first_submitted_qc>April 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>April 14, 2016</last_update_submitted>
  <last_update_submitted_qc>April 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>60 mg Duloxetine</title>
          <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment.1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Double-Blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Extension Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>60 mg Duloxetine</title>
          <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="205"/>
            <count group_id="B2" value="202"/>
            <count group_id="B3" value="407"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.17" spread="8.19"/>
                    <measurement group_id="B2" value="59.83" spread="8.40"/>
                    <measurement group_id="B3" value="61.14" spread="8.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Brief Pain Inventory (BPI) 24-hour Average Pain Score</title>
        <description>BPI is a self-reported scale that measures the severity of pain based on the average pain during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Brief Pain Inventory (BPI) 24-hour Average Pain Score</title>
          <description>BPI is a self-reported scale that measures the severity of pain based on the average pain during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="0.11"/>
                    <measurement group_id="O2" value="-1.73" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impressions of Improvement (PGI-I) Score</title>
        <description>PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>13 Weeks</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impressions of Improvement (PGI-I) Score</title>
          <description>PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.07"/>
                    <measurement group_id="O2" value="3.09" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total and Subscale Scores</title>
        <description>WOMAC consists of 24 items divided into 3 subscales:Pain(5 items):during walking,using stairs,in bed,sitting or lying,and standing Stiffness;(2 items):after first waking and later in the day Physical Function;(17 items):stair use,rising from sitting, standing, bending,walking,getting in/out of a car,shopping,putting on/taking off socks,rising from bed,lying in bed,getting in/out of bath,sitting,getting on/off toilet,heavy household duties,light household duties.Each question is answered using a 5-point Likert scale(0 to 4).Pain subscale has a range of scores of 0(none) to 20(extreme).Stiffness subscale has a range of scores of 0(none) to 8(extreme).Physical function subscale has a range of scores of 0(none) to 68(extreme).Total score ranges from 0(none) to 96(extreme).Least squares(LS) mean was calculated using analysis of covariance(ANCOVA) and adjusted for treatment, pooled investigator,and baseline score.Last observation carried forward (LOCF) method was be used for these analyses.</description>
        <time_frame>Baseline, Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total and Subscale Scores</title>
          <description>WOMAC consists of 24 items divided into 3 subscales:Pain(5 items):during walking,using stairs,in bed,sitting or lying,and standing Stiffness;(2 items):after first waking and later in the day Physical Function;(17 items):stair use,rising from sitting, standing, bending,walking,getting in/out of a car,shopping,putting on/taking off socks,rising from bed,lying in bed,getting in/out of bath,sitting,getting on/off toilet,heavy household duties,light household duties.Each question is answered using a 5-point Likert scale(0 to 4).Pain subscale has a range of scores of 0(none) to 20(extreme).Stiffness subscale has a range of scores of 0(none) to 8(extreme).Physical function subscale has a range of scores of 0(none) to 68(extreme).Total score ranges from 0(none) to 96(extreme).Least squares(LS) mean was calculated using analysis of covariance(ANCOVA) and adjusted for treatment, pooled investigator,and baseline score.Last observation carried forward (LOCF) method was be used for these analyses.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.58" spread="0.92"/>
                    <measurement group_id="O2" value="-10.09" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" spread="0.21"/>
                    <measurement group_id="O2" value="-2.32" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.64" spread="0.68"/>
                    <measurement group_id="O2" value="-7.28" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.10"/>
                    <measurement group_id="O2" value="-0.44" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.62</ci_lower_limit>
            <ci_upper_limit>-1.35</ci_upper_limit>
            <estimate_desc>Total Score</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
            <estimate_desc>Pain</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.95</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
            <estimate_desc>Physical Function</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
            <estimate_desc>Stiffness</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score</title>
        <description>CGI-S measures severity of illness at the time of assessment compared with start of treatment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline,13 Weeks</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score</title>
          <description>CGI-S measures severity of illness at the time of assessment compared with start of treatment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.05"/>
                    <measurement group_id="O2" value="-0.53" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory (BPI) Severity</title>
        <description>BPI Severity of Worst Pain is self-reported scale that measures the severity of pain based on the worst pain experienced during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). BPI Severity of Least Pain is a self-reported scale that measures the severity of pain based on the least pain experienced during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). BPI Severity of Right Now Pain is a self-reported scale that measures the severity of pain based on the pain right now. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory (BPI) Severity</title>
          <description>BPI Severity of Worst Pain is self-reported scale that measures the severity of pain based on the worst pain experienced during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). BPI Severity of Least Pain is a self-reported scale that measures the severity of pain based on the least pain experienced during the past 24-hours. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). BPI Severity of Right Now Pain is a self-reported scale that measures the severity of pain based on the pain right now. The severity scores ranged from 0 (no pain) to 10 (pain as severe as you can imagine). Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPI Severity of Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="0.14"/>
                    <measurement group_id="O2" value="-2.00" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI Severity of Least Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.12"/>
                    <measurement group_id="O2" value="-1.20" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI Severity of Right Now Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="0.14"/>
                    <measurement group_id="O2" value="-1.74" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
            <estimate_desc>BPI Severity of Worst Pain</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
            <estimate_desc>BPI Severity of Least Pain</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
            <estimate_desc>BPI Severity of Right Now Pain</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory (BPI) Interference</title>
        <description>BPI Interference Average Score is a self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people,sleep, and enjoyment of life.The average Interference scores ranged from 0 to 10. General activity, mood,walking ability, normal work,relations with other people, sleep and enjoyment of life is each is a self-reported scale that measures the interference of pain in the past 24 hours on general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life.The Interference scores ranged from 0 (does not interfere) to 10 (completely interferes).Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
        <time_frame>Baseline, Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory (BPI) Interference</title>
          <description>BPI Interference Average Score is a self-reported scale that measures interference of pain on average of the 7 questions assessing the interference of pain for general activity, mood, walking ability, normal work, relations with other people,sleep, and enjoyment of life.The average Interference scores ranged from 0 to 10. General activity, mood,walking ability, normal work,relations with other people, sleep and enjoyment of life is each is a self-reported scale that measures the interference of pain in the past 24 hours on general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life.The Interference scores ranged from 0 (does not interfere) to 10 (completely interferes).Least squares (LS) mean was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, pooled investigator, visit, and treatment-by-visit interaction, as well as baseline score and baseline score-by-visit interaction.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPI Interference Average Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="0.10"/>
                    <measurement group_id="O2" value="-1.36" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="0.14"/>
                    <measurement group_id="O2" value="-1.83" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="0.13"/>
                    <measurement group_id="O2" value="-1.04" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking ability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="0.14"/>
                    <measurement group_id="O2" value="-1.88" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="0.14"/>
                    <measurement group_id="O2" value="-1.76" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relations with other people</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="0.11"/>
                    <measurement group_id="O2" value="-0.84" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="0.14"/>
                    <measurement group_id="O2" value="-0.99" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.13"/>
                    <measurement group_id="O2" value="-1.07" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
            <estimate_desc>BPI Interference Average Score</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
            <estimate_desc>General activity</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
            <estimate_desc>Mood</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
            <estimate_desc>Walking ability</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>Normal work (includes both work outside the home and housework)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>Relations with other people</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
            <estimate_desc>Sleep</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
            <estimate_desc>Enjoyment of life</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hospital Anxiety and Depression Scale-Depression (HADS-D) or HADS-Anxiety (HADS-A) Subscale Scores</title>
        <description>HADS is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale [0 (low level of anxiety or depression) to 3 (high level of anxiety or depression)], giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale were considered to be a 'significant' case of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' Mean was calculated using analysis of covariance (ANCOVA) and adjusted for treatment, pooled investigator, and baseline score. The last observation carried forward (LOCF) method will be used for these analyses.</description>
        <time_frame>Baseline, Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hospital Anxiety and Depression Scale-Depression (HADS-D) or HADS-Anxiety (HADS-A) Subscale Scores</title>
          <description>HADS is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item was rated on a 4-point scale [0 (low level of anxiety or depression) to 3 (high level of anxiety or depression)], giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale were considered to be a 'significant' case of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.' Mean was calculated using analysis of covariance (ANCOVA) and adjusted for treatment, pooled investigator, and baseline score. The last observation carried forward (LOCF) method will be used for these analyses.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Depression Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="2.05"/>
                    <measurement group_id="O2" value="-0.10" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="2.58"/>
                    <measurement group_id="O2" value="0.08" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brief Pain Inventory (BPI) Average Pain Intensity Scores, Hospital Anxiety and Depression Scale (HADS) Depression Subscale (HADS-D) and HADS Anxiety Subscale (HADS-A)</title>
        <description>Evaluation on whether the change in BPI average pain intensity scores is a direct analgesic effect of duloxetine and is independent of treatment effect on mood, as measured by Hospital Anxiety and Depression Scale (HADS) depression subscale (HADS-D), or anxiety as measured by HADS anxiety subscale (HADS-A). Path analysis for the direct analgesic effect was used to test the null hypothesis that the change in BPI average pain severity depends on the improvement of HADS-D or HADS-A, versus the alternative that the improvement in BPI average pain severity is due to a direct analgesic effect of the treatment and not dependent upon the improvement in depression and anxiety symptoms.</description>
        <time_frame>Baseline, Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants (60 mg Duloxetine &amp; Placebo)</title>
            <description>Duloxetine:
Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg.
Placebo:
Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase:
1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brief Pain Inventory (BPI) Average Pain Intensity Scores, Hospital Anxiety and Depression Scale (HADS) Depression Subscale (HADS-D) and HADS Anxiety Subscale (HADS-A)</title>
          <description>Evaluation on whether the change in BPI average pain intensity scores is a direct analgesic effect of duloxetine and is independent of treatment effect on mood, as measured by Hospital Anxiety and Depression Scale (HADS) depression subscale (HADS-D), or anxiety as measured by HADS anxiety subscale (HADS-A). Path analysis for the direct analgesic effect was used to test the null hypothesis that the change in BPI average pain severity depends on the improvement of HADS-D or HADS-A, versus the alternative that the improvement in BPI average pain severity is due to a direct analgesic effect of the treatment and not dependent upon the improvement in depression and anxiety symptoms.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPI average pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HADS-Depression subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HADS-Anxiety subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Path analysis for the direct analgesic effect was used to test the null hypothesis that the change in BPI average pain severity depends on the improvement of HADS-D or HADS-A, versus the alternative that the improvement in BPI average pain severity is due to a direct analgesic effect of the treatment and not dependent upon the improvement in depression and anxiety symptoms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Regression, Linear</method>
            <param_type>Total Effect</param_type>
            <param_value>97.49</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Reduction of ≥30% and ≥50% in BPI Average Pain Score</title>
        <description>Pain severity was measured using an 11 point BPI scale from 0 (no pain) to 10 (worst pain) to determine average pain in the past 24 hours (average pain). A 30% (or 50%) improvement was defined as a ≥30% (or ≥50%) reduction in BPI pain severity from baseline to endpoint. Percentage of participants = (number of participants with ≥30% or ≥50% pain reduction / total number of participants in treatment group) * 100.The last observation carried forward (LOCF) method will be used for these analyses.</description>
        <time_frame>Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reduction of ≥30% and ≥50% in BPI Average Pain Score</title>
          <description>Pain severity was measured using an 11 point BPI scale from 0 (no pain) to 10 (worst pain) to determine average pain in the past 24 hours (average pain). A 30% (or 50%) improvement was defined as a ≥30% (or ≥50%) reduction in BPI pain severity from baseline to endpoint. Percentage of participants = (number of participants with ≥30% or ≥50% pain reduction / total number of participants in treatment group) * 100.The last observation carried forward (LOCF) method will be used for these analyses.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with &gt;=30% Reductions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.40"/>
                    <measurement group_id="O2" value="49.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with &gt;=50% Reductions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.80"/>
                    <measurement group_id="O2" value="34.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response to Treatment on Patient Global Impression-Improvement (PGI-I) at Endpoint</title>
        <description>PGI-I measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). Response to treatment is defined by endpoint PGI rating of either “much better” or “very much better”.The last observation carried forward (LOCF) method will be used for these analyses.</description>
        <time_frame>Week 13</time_frame>
        <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg Duloxetine</title>
            <description>Double Blind Treatment Phase:
60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks.
Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double Blind Treatment Phase:
Placebo administered by mouth once a day (QD) for 13 weeks.
Extension Treatment Phase:
60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response to Treatment on Patient Global Impression-Improvement (PGI-I) at Endpoint</title>
          <description>PGI-I measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Scores ranged from 1 (very much better) to 7 (very much worse). Response to treatment is defined by endpoint PGI rating of either “much better” or “very much better”.The last observation carried forward (LOCF) method will be used for these analyses.</description>
          <population>All participants who were randomized and had a baseline and at least 1 post-baseline observation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response to Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1=Very much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10"/>
                    <measurement group_id="O2" value="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2=Much better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.60"/>
                    <measurement group_id="O2" value="17.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3=A little better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.70"/>
                    <measurement group_id="O2" value="51.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4=The same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.10"/>
                    <measurement group_id="O2" value="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5=A little worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50"/>
                    <measurement group_id="O2" value="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6=Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 = Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants who received at least one dose of study drug. One participant in placebo arm did not receive study drug during the extension period.</desc>
      <group_list>
        <group group_id="E1">
          <title>60 mg Duloxetine Double Blind</title>
          <description>60 mg duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Double Blind</title>
          <description>Placebo administered by mouth once a day (QD) for 13 weeks.</description>
        </group>
        <group group_id="E3">
          <title>60 mg Duloxetine Extention</title>
          <description>60 mg duloxetine administered by mouth QD for 13 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo/60 mg Duloxetine Extention</title>
          <description>60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.</description>
        </group>
        <group group_id="E5">
          <title>60 mg Duloxetine Taper</title>
          <description>1-week taper - participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs).</description>
        </group>
        <group group_id="E6">
          <title>Placebo Taper</title>
          <description>Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="166"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="175"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="199"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyschezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="199"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Therapeutic response unexpected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urine output increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dreamy state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="199"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypohidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

